Decreases arthritis clinical score, edema, and leucocyte recruitment. Reduces local eicosanoid levels (e.g., LTB4, PGE2, and TXB2) in an ALX/FPR2-deperndent manner. The gene discussed is FPR2; the disease is arthritic joint disease.